Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) was proposed as a Joint Technology Initiative under the EU’s Seventh Framework Programme for Research (FP7).  First calls under this initiative were been published on 30th April 2008, including two in the respiratory field (understanding severe asthma and patient reported outcomes in COPD).

On 27 November 2009, the European Commission and the pharmaceutical industry launch second call for research proposal towards more efficient drug development methods. In the Efficacy Pillar the areas of cancer, infectious diseases and inflammation are seen as priorities for this year.

The application deadline, for the IMI calls, 1st stage is 8th February 2010

List of the topics of IMI's 2nd Call for proposals:

1. Imaging biomarkers for anticancer drug development.
2. New tools for target validation to improve drug efficacy.
3. Molecular biomarkers: accelerating cancer therapy development and refining patient care.
4. Identification and development of rapid point-of-care diagnostic tests for bacterial diagnosis to facilitate conduct of clinical trials and clinical practice.
5. Understanding aberrant adaptive immunity mechanisms.
6. Translational research in chronic immune-mediated disease: bridging between animal models and humans.
7. Drug/disease modelling: library & framework.
8. Open pharmacological space.
9. Electronic Health Records (EHR).
   

To access the complete information package, please go to: http://www.imi.europa.eu/calls-02_en.html